1315 Capital Leads Growth Investment in Experic
October 29, 2024
Experic, a Cranbury, New Jersey-based CDMO and clinical trial supply services firm, received a growth capital investment led by 1315 Capital with participation from existing investors East Seattle Partners, Harro Höfliger Packaging Systems, Inc., and Kineticos Ventures. The capital will be used to enhance Experic’s manufacturing capabilities and accelerate its international expansion to better serve biopharmaceutical clients.
- Buyers
- 1315 Capital, East Seattle Partners, Harro Höfliger Packaging Systems, Inc., Kineticos Ventures
- Targets
- Experic
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
1315 Capital Backs USpharma Ltd. with Growth Equity Investment
June 30, 2025
Pharmaceuticals
USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.
-
1315 Capital Provides Growth Financing to ProSciento
September 10, 2020
Healthcare Services
ProSciento, a San Diego–based specialty clinical research organization focused on NASH, diabetes and obesity, closed a growth financing round with healthcare investor 1315 Capital. The capital will support expansion of ProSciento's CRO operations and growth of its patient access solutions, including the NASH PASS registry.
-
1315 Capital Invests in Primrose Bio
June 17, 2024
Biotechnology
1315 Capital, a Philadelphia-based healthcare-focused growth equity firm, made a significant equity investment in Primrose Bio to support development and commercial expansion of Primrose’s nucleic acid and protein manufacturing technologies. The funding will accelerate commercialization of the company’s Prima RNApols, Pfenex expression system, and PeliCRM carrier protein for therapeutics and vaccines.
-
VSS Capital Partners Makes Growth Investment in Eximia Research Network
October 4, 2023
Healthcare Services
VSS Capital Partners has made a growth capital investment to form and scale Eximia Research Network, a multi-therapeutic clinical research site network led by CEO Dr. Ella Grach. The investment establishes Eximia as a platform company that will leverage centralized services and a strategic partnership with Sundance Clinical Research to expand clinical trial delivery and access.
-
Symeres Acquires Exemplify BioPharma
October 25, 2022
Pharmaceuticals
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
Kain Capital Invests in Excelsior Integrated Medical
August 24, 2020
Healthcare Services
Kain Capital LLC has made a growth investment in Excelsior Integrated Medical, a New York City–based primary care physician group serving over 60,000 patients across 37 locations with roughly 75 providers. The capital will support Excelsior's continued shift to a value‑based, global capitation model and expansion of its provider base, with the goal of replicating the model beyond the local community.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.